Absolutely. I would say that for us, because we're working a lot with the earlier stage companies, our sweet spot sits in the up to $20-million range of investment rounds.
I find the biggest challenge that our companies and VCs face here in Canada is that when you're dealing with the industrial bioeconomy, you're dealing with large capital assets that need to be built to produce things like biofuels, biochemicals and biomaterials. When you start requiring capital in excess of $100 million to execute a project, it's way beyond the capability of a group like ours to do that, and it does require a significant consortia of groups.
I think that's where you find the biggest problem here. We need to find those levels of funding to tackle those sorts of projects, and this is requiring us to attract international funds into our projects.